Conference Coverage

VIDEO: Ken Gordon’s pro tips on using biologics in psoriasis


 

AT THE CARIBBEAN DERMATOLOGY SYMPOSIUM

References

GRAND CAYMAN – When considering the use of biologic therapy for psoriasis patients who are at greater risk of cancer or of serious infection, Dr. Kenneth B. Gordon advises clinicians to “look at the patient in front of you” and the impact the disease is having on them.

In an interview at the annual Caribbean Dermatology Symposium, Dr. Gordon, professor of dermatology at Northwestern University, Chicago, discusses the use of biologics to treat psoriasis in patients with a history of cancer, patients at an increased risk for serious infections (such as those with chronic renal disease or diabetes), as well as patients with HIV, who can have significant psoriasis.

He also provides some recommendations on counseling patients and discusses the use of biologics in children with psoriasis.

The meeting is provided by Global Academy for Medical Education. Global Academy and this news organization are owned by the same parent company.

The video associated with this article is no longer available on this site. Please view all of our videos on the MDedge YouTube channel.

wmcknight@frontlinemedcom.com

On Twitter @whitneymcknight

This article was updated 1/31/2016.

Recommended Reading

Poor response to third anti-TNF agent seen in most psoriatic arthritis patients
MDedge Rheumatology
‘Cytokine converter’ cells alleviate psoriasis in mice
MDedge Rheumatology
Secukinumab cut ankylosing spondylitis symptoms in MEASURE trials
MDedge Rheumatology
More comorbidity with PsA form of spondyloarthritis
MDedge Rheumatology
Methotrexate has a role in treating articular manifestations of psoriatic arthritis
MDedge Rheumatology
ACR: Etanercept during pregnancy doubles the odds of major malformations
MDedge Rheumatology
EADV: New oral psoriasis drug shows excellent safety
MDedge Rheumatology
EADV: Family history of cardiovascular disease is key in psoriasis patients
MDedge Rheumatology
Secukinumab receives FDA approval for psoriatic arthritis, ankylosing spondylitis
MDedge Rheumatology
Step therapy and biologics: An easier road ahead?
MDedge Rheumatology